Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Cash from Operations (2019 - 2025)

Historic Cash from Operations for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to -$67.8 million.

  • Nurix Therapeutics' Cash from Operations fell 3913.97% to -$67.8 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$249.5 million, marking a year-over-year decrease of 4454.7%. This contributed to the annual value of -$249.5 million for FY2025, which is 4454.7% down from last year.
  • Per Nurix Therapeutics' latest filing, its Cash from Operations stood at -$67.8 million for Q4 2025, which was down 3913.97% from -$57.4 million recorded in Q3 2025.
  • In the past 5 years, Nurix Therapeutics' Cash from Operations ranged from a high of $26.7 million in Q4 2023 and a low of -$67.8 million during Q4 2025
  • Its 5-year average for Cash from Operations is -$37.4 million, with a median of -$41.5 million in 2023.
  • Its Cash from Operations has fluctuated over the past 5 years, first crashed by 62936.79% in 2022, then surged by 17031.75% in 2023.
  • Nurix Therapeutics' Cash from Operations (Quarter) stood at -$30.9 million in 2021, then decreased by 22.79% to -$38.0 million in 2022, then soared by 170.32% to $26.7 million in 2023, then plummeted by 282.66% to -$48.8 million in 2024, then crashed by 39.14% to -$67.8 million in 2025.
  • Its Cash from Operations stands at -$67.8 million for Q4 2025, versus -$57.4 million for Q3 2025 and -$63.2 million for Q2 2025.